Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Liposarcoma × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 13 Neoplasms 8 Carcinoma, Hepatocellular 8 Thyroid Neoplasms 5 Melanoma 5 Endometrial Neoplasms 5 Carcinoma, Renal Cell 5 Squamous Cell Carcinoma of Head and Neck 4 Recurrence 4 Carcinoma, Non-Small-Cell Lung 4 Thyroid Cancer, Papillary 3 Colorectal Neoplasms 3 Adenocarcinoma, Follicular 3 Stomach Neoplasms 2 Ovarian Neoplasms 2 Osteosarcoma 2 Neoplasm Metastasis 2 Lymphoma 2 Glioma 2 Carcinoma, Transitional Cell 2 Carcinoma 2 Biliary Tract Neoplasms 2 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 Thyroid cancer, medullary 1 Thyroid cancer, Hurthle cell 1 Thyroid Diseases 1 Thyroid Carcinoma, Anaplastic 1 Solid Tumors 1 Sarcoma 1

Interventions

Doxorubicin 6 pazopanib 4 Trabectedin 4 Radiotherapy 3 temsirolimus 2 eribulin 2 Sunitinib 2 Radiotherapy, Conformal 2 Ifosfamide 2 Dexamethasone 2 sitravatinib 1 selinexor 1 saracatinib 1 romidepsin 1 regorafenib 1 plitidepsin 1 pembrolizumab 1 palbociclib 1 olaratumab 1 milademetan 1 liposomal doxorubicin 1 lenvatinib 1 indolepropanol phosphate 1 efatutazone 1 cixutumumab 1 brigimadlin 1 avelumab 1 atezolizumab 1 Watchful Waiting 1 Topotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03526679 2025-12-05

LEADER

National Taiwan University Hospital

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡